Physician profile
Patrick D Morton
NPI 1578598702
$7,802.62
in general payments reported to CMS, 2019-2025
41 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,783 · 2020: $674 · 2021: $910 · 2022: $955 · 2023: $1,264 · 2024: $1,093 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,480.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,640.41 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $1,007.41 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $467.73 | 2021-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $434.31 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $347.69 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $320.75 | 2019-2024 | Xarelto |
| Amgen INC. | $318.22 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $296.34 | 2019-2024 | Proclaim, Eterna, Freestyle Libre |
| Astrazeneca Pharmaceuticals Lp | $279.41 | 2019-2024 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.69 | 2019-2025 | Xifaxan, Trulance |
| Heartflow, INC. | $263.59 | 2023-2024 | Ffrct |
| Glaxosmithkline, LLC. | $262.14 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Sunovion Pharmaceuticals INC. | $237.69 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $187.73 | 2024 | Camzyos, Eliquis |
| Neurocrine Biosciences, INC. | $176.16 | 2019-2024 | Ingrezza |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Morton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.